Last reviewed · How we verify
NCT06313346: FLORABIOTIC
Effect of a Probiotic on Microbiota Associated with the Immune System and Inflammation.
NA trial testing Probiotic in Probiotic in 60 participants. Completed in 15 June 2024.
24 April 2024
Quick facts
| Lead sponsor | Clinica Universidad de Navarra, Universidad de Navarra |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 60 |
| Start date | 8 January 2024 |
| Primary completion | 24 April 2024 |
| Estimated completion | 15 June 2024 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Probiotic
- Placebo
Conditions studied
- Probiotic — all drugs for Probiotic →
- Microbiota — all drugs for Microbiota →
Sponsor
Clinica Universidad de Navarra, Universidad de Navarra
Who can join
Adults 40 to 65, any sex, with Probiotic or Microbiota. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this randomized clinical trial is to learn about the effect of consuming a probiotic on the microbiota associated with immune health and inflammation in healthy women and men after 6 weeks of intervention. The main questions to answer are: 1. To study changes in the intestinal microbiota associated with immune health and inflammation related to probiotic intake. 2. To evaluate changes in salivary cortisol after ingestion of the probiotic. 3. To compile the number and intensity of catarrhal episodes suffered by the participants along the study. For this purpose, a randomized, double blind parallel study has been designed. Target sample size is 60 subjects. Participants will be allocated in two groups for 6 weeks: * Experimental group (n=30): daily consumption of one probiotic capsule. * Placebo group (n=30): daily consumption of one placebo capsule.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06313346
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Probiotic
Trials testing the same drug.
- NCT07529457 — Akk09 in Adults With Constipation · NA · not yet recruiting
- NCT07507955 — Probiotics for Constipation Relief in Adults · NA · not yet recruiting
- NCT07462481 — Probiotic Improve Constipation · NA · recruiting
- NCT07511855 — Stress-buffering and Sleep Disturbance-resilient Effects of a Dual Bifidobacterium Longum Combination Under Short-term T · Phase 2 · not yet recruiting
- NCT07474064 — Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC · Phase 2 · not yet recruiting
Other recruiting trials for Probiotic
Currently open trials in the same condition.
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
- NCT07356869 — Probiotic-Based Versus Ethyl Lauroyl Arginate-Containing Mouthwashes on Streptococcus Mutans Counts, Dental Plaque Accum · NA · recruiting
- NCT06856434 — Effect of Probiotic's Consumption on Several Markers in Perforated Appendix Patients With Diffuse Peritonitis · NA · active not recruiting
- NCT06960369 — Efficacy of Repeated Transcranial Magnetic Stimulation Combined With a Live Probiotic Tablet (Combined Bifidobacterium, · Phase 1 · recruiting
- NCT06724185 — Effects of LP28 on Immunity Enhancement in the Elderly · NA · recruiting
Other Clinica Universidad de Navarra, Universidad de Navarra trials
Trials by the same sponsor.
- NCT07370571 — NO AXILLARY SURGERY IN EARLY BREAST CANCER (OXIGENATE) · not yet recruiting
- NCT07165431 — Effect of a Postbiotic Supplementation in Overweight and Obese Subjects: A Randomized Controlled Trial (PARABIOTICS-2). · NA · recruiting
- NCT07447440 — Role of Pro-Resolving Lipid Mediators in Obesity-Associated Diseases · recruiting
- NCT07191210 — Co-Designed Comprehensive Transition Programme for First-Line Nurse Managers · NA · not yet recruiting
- NCT07132060 — MRI-guided Dose Intensification Program Locally Advanced Pancreatic Cancer · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06313346 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Clinica Universidad de Navarra, Universidad de Navarra
- Last refreshed: 19 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06313346.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing